IMMUNO-COV™ – The Test for Antibodies that Block SARS-CoV-2 Infection Read More

April 7, 2022

Vyriad creates potential oral covid vaccine

An interview with Dr. Stephen Russell discussing the development of an oral vaccine from Vyriad.

About Vyriad, Inc.

 Vyriad is a clinical-stage company developing virus-based therapeutics, focusing initially on proprietary oncolytic virus therapies for the treatment of cancers with significant unmet needs. Founded by scientists at Mayo Clinic and the University of Miami, Vyriad programs viruses to selectively attack cancer cells, thereby igniting antitumor immune responses that can complete the process of tumor destruction and prevent disease recurrence. Our lead platforms, derived from either vesicular stomatitis virus (VSV) or measles virus, are being evaluated in ongoing Phase 1-2 clinical trials addressing multiple cancer types. Vyriad and Regeneron (NASDAQ: REGN) are engaged in a broad strategic agreement for the discovery and development of new oncolytic virus treatments for cancer leveraging Vyriad’s VSV platform and Regeneron’s PD-1 inhibitor Libtayo® (cemiplimab) as well as its unmatched antibody discovery capabilities. Vyriad is a privately held company based in Rochester, Minnesota.  For more information, visit www.vyriad.com.

Media Inquiries

For inquiries, please contact mediarelations@vyriad.com